We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Prothena

News List

Prothena and Novo Nordisk Agreement for ATTR Amyloidosis Program americanpharmaceuticalreview
July 13, 2021
Novo Nordisk A/S has acquired Prothena Corporation’s clinical-stage antibody PRX004 and broader ATTR amyloidosis program.
Prothena announces new COO biospectrumasia
June 27, 2018
Nguyen currently serves on the board of directors of Sierra Oncology, Inc., a public clinical-stage oncology company and Rain Therapeutics Inc., a private clinical-stage oncology company.
After AL amyloidosis flop, Prothena slashes workforce by 57% fiercebiotech
May 29, 2018
To say that Prothena had a turbulent year would be an understatement. In the span of a month, the biotech went from inking an R&D deal with Celgene worth up to $2 billion to dumping its lead asset
Prothena scratches MCAM psoriasis antibody after negative trial fiercebiotech
September 30, 2017
Prothena had previously suggested that the drug could have potential in progressive MS, which is particularly resistant to current therapies.